Dew, so even if there are multiple 'outliers' with a marked increase in PFS or OS who all seem to come from the Squamous group and this is statistically significant for that subgroup, that data is not sufficient for the narrower label of Squamous approval if the summed trial data for NSCLC does not meet 'statsig?' Just trying to be sure I understand correctly...
Market Data 
Markets 
AI
